Knockdown of mesenchymal stem cell-derived exosomal LOC100129516 suppresses the symptoms of atherosclerosis via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway

LIMIN SUN1,2, XIN HE3, TAO ZHANG2, YALING HAN4 and GUIZHOU TAO1,3

1Department of Medicine, Soochow University, Suzhou, Jiangsu 215123; Departments of 2General Practice and 3Cardiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001; 4Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P.R. China

Received June 1, 2021; Accepted September 9, 2021

DOI: 10.3892/ijmm.2021.5041

Abstract. Mesenchymal stem cell (MSC) therapy has potential applications in treating atherosclerosis and coronary heart disease (CAD). Previous studies have demonstrated that MSCs are the most preferable sources of therapeutic exosomes, which carry long non-coding RNAs and participate in the progression of atherosclerosis. The results of our previous bioinformatics study demonstrated that the levels of LOC100129516 were significantly upregulated in peripheral blood mononuclear cells obtained from patients with CAD. However, the biological role of LOC100129516 in the development of atherosclerosis remains to be elucidated. In the present study, THP-1 cells were treated with oxidized low-density lipoproteins to induce foam cell formation in vitro. Reverse transcription-quantitative PCR (RT-qPCR) was performed to detect the levels of LOC100129516 in THP-1 macrophage-derived foam cells. In addition, an in vivo model of atherosclerosis was established using Apolipoprotein E (ApoE) knockout (ApoE−/−) mice. The results of the RT-qPCR assays demonstrated that the levels of LOC100129516 were upregulated in TPH-1 macrophage-derived foam cells. MSC-derived exosomes were able to deliver small interfering (si)-LOC100129516 to THP-1 cells to reduce the levels of LOC100129516. Moreover, transfection of si-LOC100129516 via exosomal delivery significantly decreased the levels of total cholesterol (TC), free cholesterol and cholesterol ester in TPH-1 macrophage-derived foam cells. Exosomal-mediated delivery of si-LOC100129516 decreased TC levels and low-density lipoprotein levels in the ApoE−/− atherosclerosis mouse model. Mechanistically, exosomal-mediated delivery of si-LOC100129516 promoted cholesterol efflux by activating the peroxisome proliferator-activated receptor γ (PPARγ)/liver X receptor α (LXRα)/phospholipid-transporting ATPase ABCA1 (ABCA1) signaling pathway in vitro and in vivo. Collectively, these results suggested that exosomal-mediated delivery of si-LOC100129516, in which the exosomes were derived from MSCs, promoted cholesterol efflux and suppressed intracellular lipid accumulation, ultimately alleviating the progression of atherosclerosis via stimulation of the PPARγ/LXRα/ABCA1 signaling pathway.

Introduction

Atherosclerosis is a chronic inflammatory disease characterized by proliferative lesions in the lining of the arteries, which has a serious impact on the quality of life of patients with the disease (1,2). Atherosclerosis involves arterial wall thickening, sclerosis, loss of elasticity and lumen narrowing (1,2), and is the primary cause of the development of coronary heart disease (CAD) (3). However, the specific cause of atherosclerosis remains to be elucidated (2). Extensive investigations into the etiology of atherosclerosis have demonstrated that it is a multi-etiological disease (4). The collective results of previous studies demonstrated that patients with hyperlipidemia, high blood pressure and diabetes, and patients who smoke experience an increased risk of developing atherosclerosis (5,6). Therapeutic methods that target atherosclerosis can be grouped according to the severity of the disease, including acute, general, drug-based, surgical and Traditional Chinese medicine-based treatments (7-10). Although current strategies for the treatment of atherosclerosis are continuously improving, the mortality rate of atherosclerosis remains high (11). Thus, further investigations into novel therapeutic methods for the treatment of atherosclerosis are required.

Macrophages are common phagocytes found in the blood, lymphatic and mammalian tissue (12), which play important roles in normal development, homeostasis, tissue repair and in the immune response to pathogens (13). Previous studies have reported that macrophages use chemotaxis induced by
inflammatory factors produced during oxidized low-density lipoprotein (ox-LDL) modification, and phagocytosis of ox-LDLs in large quantities induces the formation of foam cells, leading to the development of atherosclerotic lesions (14-16). The functional changes of macrophages are closely associated with the formation and development of atherosclerosis (14-16).

Mesenchymal stem cells (MSCs) are a type of pluripotent stem cell with self-renewal and multidirectional differentiation capacities (17). In addition, MSCs are safe and effective for tissue repair and regeneration in cardiovascular diseases, such as CAD (18). Exosomes are small membrane vesicles (40-100 nm in diameter) that are secreted by a variety of cells, including MSCs (19). Furthermore, exosomes are extensively involved in intercellular communication via transport of proteins, DNA, microRNA (miRNA/miR), long non-coding (Inc)RNA and mRNAs (20). The results of a previous study demonstrated that IncRNAs secreted by MSCs are delivered into recipient cells via exosomes, participating in the progression of CAD (21).

IncRNAs are a class of non-coding RNAs with a length of >200 nucleotides, which are involved in various regulatory processes, such as transcriptional silencing, transcriptional activation, chromosome modification and intra nuclear transport (22,23). It has previously been reported that IncRNAs are closely associated with the occurrence, development, prevention and treatment of CAD (24,25). In our previous study, bioinformatics analysis revealed that LOC100129516 expression was upregulated in peripheral blood mononuclear cells (PBMCs) from patients with CAD, compared with PBMCs from healthy controls (in press). In addition, LOC100129516 knockout exhibited a protective effect on the ox-LDL-induced proliferation inhibition of human umbilical vein endothelial cells (HUVECs).

However, the biological role of MSC-derived exosomal LOC100129516 in atherosclerosis remains to be elucidated. In the present study, MSC-derived exosomal-mediated delivery of small interfering RNA (siRNA/si)-LOC100129516 increased cholesterol excretion and suppressed intracellular lipid accumulation in THP-1 macrophage-derived foam cells and Apolipoprotein E (ApoeE) knockout (ApoeE−/−) mice with atherosclerosis. These results suggested that the exosomal-mediated delivery of si-LOC100129516 alleviated atherosclerosis development both in vitro and in vivo. Thus, the aim of the present study was to explore novel strategies for atherosclerosis treatment.

Materials and methods

Cell culture and construction of the foam cell model. The human acute monocytic leukemia cell line, THP-1, and human vascular smooth muscle cells were obtained from the American Type Culture Collection. Human bone marrow MSCs were purchased from Procell, Inc. The cells were cultured in RPMI-1640 medium containing 10% FBS and 2 mM glutamine (Sigma Aldrich; Merck KGaA) in a humidified incubator supplied with 5% CO2 at 37°C. MSCs and vascular smooth muscle cells were primary cells (commercialized), which have not been immortalized.

To construct the foam cell model, THP-1 cells or vascular smooth muscle cells were exposed to phorbol myristate acetate (100 nM; Sigma-Aldrich; Merck KGaA) for 24 h, and subsequently incubated with 50 µg/ml ox-LDL for 48 h, as described previously (26).

Reverse transcription-quantitative (RT-q)PCR. Total RNA was extracted from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, total RNA was reverse transcribed into cDNA using an EnLiNK™ 1st Strand cDNA Synthesis kit according to the manufacturer’s protocol (ELK Biotechnology, Co., Ltd.). The temperature and duration of RT were as follows: 37°C for 60 min and 85°C for 5 min. qPCR was performed using a SYBR® Premix Ex Taq™ II kit (ELK Biotechnology Co., Ltd.) on a 7900HT system (Applied Biosystems; Thermo Fisher Scientific, Inc.) as follows: 60°C for 1 min, 90°C for 15 min, followed by 40 cycles of 90°C for 15 sec and 55°C for 60 sec. β-actin was used as an internal control. The standard 2−ΔΔCT method was used for data analysis (27). The following primer sequences were used: β-actin forward, 5'-TGC CAA AAA CAT TAA GTG AGG TG-3' and reverse, 5'-TGC TGT CAC CTT CAC CGT TC-3'; and LOC100129516 forward, 5'-GAAAGGGGACTCGACCATCAT-3' and reverse, 5'-TGCCAAAAAAATAGTGAGGGT-3'.

Cell transfection. si-LOC100129516 and siRNA-control (ctrl) were purchased from Guangzhou RiboBio Co., Ltd. A total of 10 nM si-LOC100129516 or siRNA-ctrl was transfected into MSCs, THP-1 cells or vascular smooth muscle cells using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.) for 24 h. The sequences of siRNAs used were as follows: si-LOC100129516, 5'-CCCAGGCTACCATCCTCCAATAA-3' and siRNA-ctrl, 5'-CCCCATCGTACCTCCCAACAGATTA-3'.

Isolation and characterization of exosomes. Supernatant from the culture of MSCs was removed and placed into a sterile enzyme-free 15 ml centrifuge tube. The samples were centrifuged at 2,000 x g at 4°C for 30 min to remove cells and debris. A total of 0.5 ml Total Exosome Isolation reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was added to the samples. Subsequently, the exosome samples were centrifuged at 10,000 x g at 25°C for 10 min and resuspended with 100 µl PBS. The exosomes were obtained, and a BCA assay (Aspen Biosciences, LLC) was used to detect the corresponding concentration of the exosomes. Transmission electron microscopy (TEM) and Nanoparticle Tracking Analysis (NTA) assays were used to identify the exosomes, as described previously (28). Western blot analysis was used to detect the expression levels of exosomal-specific surface biomarkers, CD63 and tumor susceptibility gene 101 (TSG101).

Exosome labeling and uptake. THP-1 cells were treated with MSC-derived exosomes at 37°C for 24 h. Subsequently, cells were labeled for 24 h at 4°C with PKH26 red membrane dye (1:1,000; Biolab Co., Ltd.; cat. no. HR9070). In addition, fluorescent phalloidin dye (Thermo Fisher Scientific, Inc.) was used to label the cytoskeleton overnight at 4°C, and DAPI was used to stain the nuclei at room temperature for 10 min. Images were captured using a fluorescence microscope (magnification, x200; Olympus Corporation).
Western blot analysis. Proteins were isolated using protein lysis buffer (Beyotime Institute of Biotechnology) and quantified using a BCA protein assay kit. A total of 30 µg protein per lane was loaded on a 10% SDS gel, resolved using SDS-PAGE and transferred to a PVDF membrane. The membrane was subsequently incubated with the following primary antibodies: Anti-CD63 (1:1,000; cat. no. ab34045; Abcam), anti-TSG101 (1:1,000; cat. no. ab125011; Abcam), anti-C9D (1:1,000; cat. no. ab236630; Abcam) anti-cleaved caspase-3 (1:1,000; cat. no. ab32042; Abcam), anti-peroxisome proliferator-activated receptor γ (PPARY; 1:1,000; cat. no. ab78860; Abcam), anti-liver X receptor α (LXRx; 1:1,000; cat. no. ab176323; Abcam), anti-phospholipid-translocating ATPase ABCA1 (ABCA1; 1:1,000; cat. no. ab66217; Abcam) and β-actin (1:1,000; cat. no. ab8226; Abcam) at 4˚C overnight. Following the primary antibody incubation, membranes were incubated with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. ab7090; Abcam) at room temperature for 1 h. Subsequently, the protein bands were detected using an ECL kit (Thermo Fisher Scientific, Inc.).

ELISA. The levels of total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE) in THP-1 macrophage-derived foam cells were measured using ELISA. The levels of TC and low-density lipoprotein cholesterol (LDL-C) were also measured in the plasma of mice using ELISA kits, according to the manufacturer's protocol. The TC assay kit (cat. no. A111-1-1) and LDL-C assay kit (cat. no. A113-1-1) were obtained from Nanjing Jiancheng Bioengineering Institute. A Micro FC Content assay kit (cat. no. BC1895) was purchased from Beijing Solarbio Science & Technology Co., Ltd. The CE content was calculated using the following equation: CE = TC content - FC content.

Observation of adipocytes. Oil red O staining was used to observe the distribution of adipose cells in THP-1 macrophage-derived foam cells. Oil red O was obtained from Beijing Solarbio Science & Technology Co., Ltd. Cells were stained with Oil red O for 5 min at room temperature. The images were observed under a fluorescence microscope.

Flow cytometry assay. THP-1 cells were trypsinized and resuspended in binding buffer. Then, cells were stained with 5 µl Annexin V-FITC (BD Biosciences) and propidium iodide (PI; BD Biosciences) in the dark at 37˚C for 30 min. Flow cytometry (FACSscan™; BD Biosciences) was applied to analyze the apoptosis rate using CellQuest™ software version 5.1 (BD Biosciences).

Nitrobenzoxadiazole-labeled cholesterol efflux assay. THP-1 macrophage-derived foam cells were incubated with 1 µg/ml NBD-cholesterol in RPMI-1640 medium containing 0.2% BSA for 24 h. A total of 15 µg/ml Apolipoprotein A1 (ApoA1; Sigma-Aldrich; Merck KGaA) or 50 µg/ml high-density lipoprotein (HDL) was used to induce cholesterol efflux. A microplate reader (Tecan Infinite M200) was used to measure NBD-cholesterol efflux (515 nm).

In vivo model of atherosclerosis. Male ApoE−/− mice (n=24, age, 8 weeks; weight, 20-25 g) were purchased from the Beijing Vital River Laboratory Animal Technology Co., Ltd. Animals were housed in a specific pathogen-free animal facility with 60% humidity at a constant temperature of 24±2˚C. To establish the in vivo atherosclerosis model, animals were randomly divided into four groups: i) Control group, containing ApoE−/− mice fed on a standard 4% fat diet (cat. no. D12450B; Beijing HFK Bioscience; ii) atherosclerosis (AS) group, containing ApoE−/− mice fed on a high-fat diet with 60% of total calories derived from fat (cat. no. D12492; Beijing HFK Bioscience) and an intravenous injection of 200 µl PBS per dose; iii) siRNA-ctrl exosome (Exo) + AS; and iv) si-LOC100129516 Exo + AS groups, containing ApoE−/− mice fed on a high-fat diet, with an injection of siRNA-ctrl Exo or si-LOC100129516 Exo via the tail vein twice a week. All mice were sacrificed using CO2 (30% volume/min) and blood samples and arteries were collected for subsequent experiments. All animal procedures were approved by The Committee of the First Affiliated Hospital of Jinzhou Medical University (approval no. FAHJMU20210113). The National Institute of Health Guide for the Care and Use of Laboratory Animals was strictly followed (29).

Oil red O and hematoxylin and eosin (H&E) staining of arteries. The arteries of the mice were perfused with PBS and separated. The arteries of mice were subsequently stained with Oil red O and H&E as described previously (30).

Statistical analysis. All results are presented as the mean ± standard deviation. Data were analyzed using a one-way ANOVA followed by a Tukey's post hoc test, using GraphPad Prism software (version 7.0; GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

LOC100129516 is upregulated in THP-1 macrophage-derived foam cells. In our previous study, results of bioinformatics analysis demonstrated that the levels of LOC100129516 were upregulated in PBMCs obtained from patients with CAD. In order to identify the expression levels and role of LOC100129516 in atherosclerosis, the levels of LOC100129516 were determined. As shown in Fig. 1, the expression of LOC100129516 in THP-1 macrophage-derived foam cells was significantly higher compared with the expression levels in THP-1 macrophages.

si-LOC100129516 is transferred from MSCs to THP-1 macrophages via exosomes. MSC-based therapy has emerged as a cell-based therapy for treating atherosclerosis (31). The results of a previous study demonstrated that exosomes carrying non-coding RNAs are involved in cell-cell communication between MSCs and macrophages (18). The present study aimed to investigate whether si-LOC100129516 could be transferred from MSCs to THP-1 macrophages via exosomes. As shown in Fig. 2A, transfection of si-LOC100129516 notably decreased the levels of LOC100129516 in MSCs, compared with the siRNA-ctrl group. Furthermore, exosomes were isolated from the culture supernatant of MSCs (MSCs-Exo), and MSCs were transfected with siRNA-ctrl (siRNA-ctrl/MSCs-Exo)
Exosomal-mediated delivery of si-LOC100129516 inhibits lipid accumulation in THP-1 macrophage-derived foam cells. The role of exosomal-mediated delivery of si-LOC100129516 in lipid accumulation in THP-1 macrophage-derived foam cells was investigated. As indicated in Fig. 4A-C, ox-LDL markedly increased the levels of TC, FC and CE in THP-1 macrophages compared with the control group. However, these ox-LDL-induced changes were reversed by si-LOC100129516/MSCs-Exo. In addition, the Oil-Red O staining results indicated that ox-LDL significantly increased intracellular lipid accumulation compared with the control group. However, this phenomenon was also reversed in the presence of si-LOC100129516/MSCs-Exo (Fig. 4D). Collectively, these results demonstrated that exosomal-mediated delivery of si-LOC100129516 inhibited the lipid accumulation in THP-1 macrophage-derived foam cells.

Exosomal-mediated delivery of si-LOC100129516 increases cholesterol efflux in THP-1 macrophage-derived foam cells via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway. Reverse cholesterol transport (RCT) is a key process in removing excessive cholesterol from cells (32). HDL and ApoAI proteins serve important roles in the RCT pathway, contributing to the efflux of excess cellular cholesterol (33-35). Thus, the effect of exosomal-mediated delivery of si-LOC100129516 on cholesterol efflux was examined in the present study. As shown in Fig. 5A and B, si-LOC100129516/MSCs-Exo significantly promoted cholesterol efflux to HDL and ApoAI. In addition, the PPARγ/LXRα/ABCA1 signaling pathway plays an important role in atherosclerosis progression via promotion of cholesterol efflux, maintenance of cholesterol balance and inhibition of foam cell formation (36,37). Thus, the protein levels of PPARγ, LXRα and ABCA1 in THP-1 macrophage-derived foam cells were detected using western blot analysis. As indicated in Fig. 5C-F, ox-LDL significantly decreased the expression levels of PPARγ, LXRα and ABCA1 in THP-1 macrophages, compared with the control group. However, these changes were partially reversed by si-LOC100129516/MSCs-Exo. Thus, exosomal-mediated delivery of si-LOC100129516 increased cholesterol efflux in THP-1 macrophage-derived foam cells via increasing the activity of the PPARγ/LXRα/ABCA1 signaling pathway.

Exosomal-mediated delivery of si-LOC100129516 suppresses atherosclerosis progression in vivo via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway. To further explore the role of exosomal-mediated delivery of si-LOC100129516 on the progression in atherosclerosis, a mouse model of atherosclerosis was established. As demonstrated in Fig. 6A, the expression levels of LOC100129516 in the aortic tissues in the atherosclerotic mouse model. However, this phenomenon was reversed by si-LOC100129516/MSCs-Exo treatment. In addition, mice that were fed a high-fat diet demonstrated a distinct thickening of the blood vessel wall and notable plaque formation in the aortic tissue. However, this effect was reversed by si-LOC100129516/MSCs-Exo treatment (Fig. 6B). Moreover, the results of the Oil red O staining assay revealed lipid accumulation and atherosclerotic plaque formation in the aortic tissue of the atherosclerotic mice compared with the control group, and this was reversed.

**Figure 1. LOC100129516 expression is upregulated in THP-1 macrophage-derived foam cells.** THP-1 macrophages were treated with 50 µg/ml ox-LDL for 48 h to construct a foam cell model, and the mRNA levels of LOC100129516 in THP-1 macrophage cells and THP-1 macrophage-derived foam cells were determined. n=3. *P<0.01 vs. control group. ox-LDL, oxidized low density lipoproteins.
Figure 2. si-LOC100129516 can be transferred from MSCs to THP-1 macrophages via exosomes. (A) RT-qPCR was used to detect the levels of LOC100129516 in MSCs transfected with si-LOC100129516 or siRNA-ctrl. (B and C) Exosomes were isolated from MSCs that were transfected with si-LOC100129516 or siRNA-ctrl. Transmission electron microscopy (magnification, 200x) and Nanoparticle Tracking Analysis assays were used to identify exosomes. (D) Western blotting was used to detect expression of exosomal surface markers CD9, CD63, and TSG101. (E) RT-qPCR was used to detect the level of LOC100129516 in exosomes. (F) The MSC-derived exosomes absorbed by THP-1 macrophages were observed under a fluorescence microscope (magnification, 200x). Red color, exosome; green color, SHG44 cells; blue color, cell nucleus. Scale bar, 100 µm. (G) RT-qPCR was used to detect the levels of LOC100129516 in THP-1 macrophages after incubation with the indicated exosomes. n=3. *P<0.05, **P<0.01 vs. control group. siRNA, small interfering RNA; MSC, mesenchymal stem cell; RT-qPCR, reverse transcription-quantitative PCR; ctrl, control; TSG101, tumor susceptibility gene 101; Exo, exosome.
Si-LOC100129516/MSCs-Exo markedly reduced the plasma levels of TC and LDL-C in ApoE-/- mice with atherosclerosis (Fig. 6C). Furthermore, si-LOC100129516/MSCs-Exo significantly upregulated the expression levels of PPARγ, LXRα and ABCA1 in the aortic tissues of ApoE-/- mice with atherosclerosis (Fig. 7A-D). Collectively, these results indicated that exosomal-mediated delivery of si-LOC100129516 suppressed atherosclerosis progression in vivo via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway.

**Discussion**

MSCs have been demonstrated to be effective for the treatment of atherosclerosis, due to their ability to repair tissue, in addition to their anti-inflammatory and immunological properties (38). MSCs can be isolated from several types of tissues, including bone marrow, the umbilical cord, placenta, adipose tissue and human gingiva (39,40). MSCs that are used for the treatment of atherosclerotic plaques are primarily derived from the bone marrow (39), but can also be obtained from the gingiva (41). In addition, MSC-derived exosomes have been a key focus of research for several decades (42). Exosomes are macrovesicles 30-150 nm in size that are secreted by MSCs via a paracrine mechanism (43). Exosomes derived from MSCs carry a number of bioactive substances, such as proteins, miRNAs and IncRNAs, and play an important role in the treatment of cardiovascular diseases, such as atherosclerosis (18,43,44). A high expression level of lncRNA-Ang362 was shown to lead to a poor prognosis in patients with CAD (45). Moreover, Mao et al (46) demonstrated that MSC-derived exosomal IncRNA Krüppel-like factor 3 antisense RNA 1 alleviated the development of myocardial infarction via the miR-138-5p/Sirtuin-1 axis (46). However, the functions of a...
Figure 4. Exosomal si-LOC100129516 inhibits lipid accumulation in THP-1 macrophage-derived foam cells. MSCs were transfected with si-LOC100129516 or siRNA-ctrl. In addition, ox-LDL-treated THP-1 macrophages were incubated with exosomes derived from transfected MSCs. (A-C) The levels of TC, FC and CE in cells were measured by ELISA. (D) Oil red O staining assay was used to observe intracellular lipid accumulation. n=3. **P<0.01 vs. control group; #P<0.01, ##P<0.01 vs. ox-LDL group. siRNA, small interfering RNA; MSC, mesenchymal stem cell; ox-LDL, oxidized low density lipoproteins; ctrl, control; Exo, exosome.

Figure 5. Exosomal si-LOC100129516 increases cholesterol excretion in THP-1 macrophage-derived foam cells by increasing the activity of the PPARγ/LXRα/ABCA1 signaling pathway. MSCs were transfected with si-LOC100129516 or siRNA-ctrl. In addition, ox-LDL-treated THP-1 macrophages were incubated with exosomes derived from transfected MSCs. (A and B) Quantification of cholesterol efflux to high-density lipoprotein cholesterol and ApoA1 in cells. (C-F) Western blot assay was used to detect the expression levels of PPARγ, LXRα and ABCA1 in cells. n=3. **P<0.01 vs. control group; #P<0.01, ##P<0.01 vs. ox-LDL group. siRNA, small interfering RNA; MSC, mesenchymal stem cell; ox-LDL, oxidized low density lipoproteins; ctrl, control; PPARγ, peroxisome proliferator-activated receptor γ; LXRα, liver X receptor α; ABCA1, phospholipid-transporting ATPase ABCA1; APOA1, apolipoprotein A1; Exo, exosome.
Figure 6. Exosomal si-LOC100129516 suppresses atherosclerotic progression in vivo. (A) Reverse transcription-quantitative PCR was used to detect the levels of LOC100129516 in the aortic tissues of ApoE−/− mice. (B) Hematoxylin and eosin staining as well as Oil-red O staining were used to observe aortic plaque formation in the ApoE−/− mice. (C) ELISA kits were used to measure the levels of TC and LDL-C in the plasma of ApoE−/− mice. n=6. *P<0.01 vs. control group; **P<0.01, ***P<0.01 vs. AS group. siRNA, small interfering RNA; H&E, hematoxylin and eosin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; ctrl, control; AS, atherosclerosis; Exo, exosome.

Figure 7. Exosomal si-LOC100129516 suppresses atherosclerotic progression in vivo via upregulation of the PPARγ/LXRα/ABCA1 signaling pathway. (A-D) Western blot assays were performed to detect the expression levels of PPARγ, LXRα, and ABCA1 in the aortic tissues of ApoE−/− mice. n=6. *P<0.01 vs. control group; **P<0.01 vs. AS group. siRNA, small interfering RNA; PPARγ, peroxisome proliferator-activated receptor γ; LXRα, liver X receptor α; ABCA1, phospholipid-transporting ATPase ABCA1; ctrl, control; AS, atherosclerosis; Exo, exosome.
number of lncRNAs in atherosclerosis remain to be elucidated. Thus, it is necessary to identify novel therapeutic targets for the prevention of progression of atherosclerosis. In the present study, it was shown that exosomal LOC100129516 derived from MSCs could suppress ox-LDL-induced HUVEC growth inhibition. Thus, the present study was the first to explore the function of exosomal LOC100129516 in atherosclerosis, suggesting a novel target for the treatment of atherosclerosis.

Li et al (47) reported that the overexpression of LOC100129516 reduced lipid accumulation and increased cholesterol efflux in THP-1 macrophage-derived foam cells and in atherosclerotic plaque tissues (47). Moreover, Meng et al (48) found that downregulation of IncRNA growth arrest specific 5 reduced lipid accumulation in THP-1 macrophage-derived foam cells, thus inhibiting the progression of atherosclerosis. In the present study, MSC-derived exosomal-mediated delivery of si-LOC100129516 significantly inhibited the apoptosis, intracellular cholesterol accumulation and lipid accumulation of THP-1 macrophage-derived foam cells, consistent with Meng et al (48). In the study by Meng et al (48), GAS5 knockdown reduced EZH2-mediated transcriptional inhibition of ABCA1 via histone methylation, and ABCA1 served a vital role in atherosclerotic progression (49). Consistently, ABCA1 was found to be regulated by exosomes with downregulated levels of LOC100129516. Therefore, the similar functions between GAS5 and exosomes with downregulated LOC100129516 expression may result in this similarity. Moreover, exosomal-mediated delivery of si-LOC100129516 reduced lipid accumulation and atherosclerotic plaque formation in ApoE−/− mice with atherosclerosis. The results of the present study suggested that exosomal-mediated delivery of si-LOC100129516 inhibited atherosclerosis progression both in vitro and in vivo. Meanwhile, the present study found that exosomal-mediated delivery of si-NC could also reverse ox-LDL-induced HUVEC growth inhibition. This phenomenon may result from the fact that exosomes have a targeting effect, which can escape the phagocytosis of macrophages (50), highlighting a potential advantage of exosomes as a mode of treatment/delivery in vivo.

PPARγ is an effective cholesterol sensor and plays a major role in the treatment of atherosclerosis (51). In addition, PPARγ enhances cholesterol efflux by inducing LXRα and ABCA1 transcription (52). The results of a previous study demonstrated that downregulation of the PPARγ/LXRα/ABCA1 signaling pathway aggravated the progression of atherosclerosis (53). Zhao et al (51) revealed that miR-613 inhibited the efflux of cholesterol from THP-1 macrophage-derived foam cells by downregulating the activity of the PPARγ/LXRα/ABCA1 signaling pathway (51). Furthermore, Wang et al (54) demonstrated that chrysin enhanced the efflux of cholesterol by regulating the PPARγ/LXRα/ABCA1/ATP binding cassette subfamily G member 1 signaling pathway (54). The results of the present study revealed that si-LOC100129516/MSCs-Exo increased cholesterol excretion by upregulating the PPARγ/LXRα/ABCA1 signaling pathway in THP-1 macrophage-derived foam cells in vitro, and in ApoE−/− mice with atherosclerosis in vivo.

The present study has some limitations as follows: i) The advantages and disadvantages of exosomal si-LOC100129516 in comparison to treatment with si-LOC100129516 transfection remain unclear; and ii) more in-depth analysis of the signaling pathways regulated by exosomal LOC100129516 in ox-LDL-treated HUVECs is required. In conclusion, MSC-derived exosomal-mediated delivery of si-LOC100129516 promoted cholesterol efflux and suppressed intracellular lipid accumulation, thus alleviating the progression of atherosclerosis by stimulating the PPARγ/LXRα/ABCA1 signaling pathway. The results of the present study highlighted that LOC10012951 may act as a potential target for novel therapeutic strategies in the treatment of atherosclerosis.

Acknowledgements

Not applicable.

Funding

This trial is a physician-initiated study and is supported by a research fund from the Chinese National Key R&D project (contract IDs: 2016YFC1301303 and 2016YFC1301300).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

LS made major contributions to the conception and design of the study, as well as the drafting of the manuscript. XH and TZ were responsible for data analysis, data interpretation and manuscript revision. GT and YH made substantial contributions to conception and design of the study, and revised the manuscript critically for important intellectual content. All authors have read and approved the final manuscript. YH and LS confirmed the authenticity of all the raw data.

Ethics approval and consent to participate

All animal procedures were approved by the Committee of the First Affiliated Hospital of Jinzhou Medical University (approval no. FAHJM/20210113). The National Institute of Health Guide for the Care and Use of Laboratory Animals was strictly followed.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Falk E: Pathogenesis of atherosclerosis. J Am Coll Cardiol 47: C7-C12, 2006.
2. Tedgui A and Mallat Z: Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 86: 515-581, 2006.
3. Weber C and Noels H: Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 17: 1410‑1422, 2011.

4. Lechner K, von Schacky C, McKenzie AL, Worm N, Nixdorf U, Lechner B, Kränke R, Näf M, Kuchelmeister K, and lifestyle factors and traditional risk factors. Eur J Prev Cardiol 27: 394‑406, 2020.

5. Shoebi S: Diagnostic and thoruistic microRNAs in the pathogenesis of atherosclerosis. Acta Physiol (Oxf) 228: e13335, 2020.

6. Kaur R and Sawhney M: Atherosclerosis: Questions and quandaries. Atherosclerosis 277: 136‑144, 2018.

7. Vaidyanathan K and Gopalakrishnan S: Nanomedicine in the diagnosis and treatment of atherosclerosis - a systematic review. Cardiovasc Hematol Disord Drug Targets 17: 119‑131, 2017.

8. Assof O, Di Gregorio K, Maegdefessel L and Johnson JL: Non-coding RNAs in cardiovascular biology and atherosclerosis. Cardiovasc Res 115: 1732‑1756, 2020.

9. Sarayba C, Nicolaes GA and Lutgens E: Targeting the adaptive immune system: New strategies in the treatment of atherosclerosis. Expert Rev Clin Pharmacol 8: 297‑313, 2015.

10. Wang N, Niimi M, Watanabe T, Wang Y, Liang J and Fan J: Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries. Atherosclerosis 277: 136‑144, 2018.

11. Kaur R and Sawhney M: Atherosclerosis: Questions and quandaries. Atherosclerosis 277: 136‑144, 2018.

12. Yen H, Yang Y, Sun X, Tian F, Guo S, Wang W, Tian Z, Jin H, Zhang B and Tian Y: Sonodynamic therapy‑induced foam cells apoptosis‑activates thephagocyticPPAR‑LRXR‑α ABCA1/ABC1 pathway and promotes cholesterol efflux in advanced plaque. Atherosclerosis 277: 136‑144, 2018.

13. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fisher MC, Frank J, Francol O and Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 12: 121‑131, 2005.

14. Talbot CPJ, Plat J, Ritsch A and Mensink RP: Determinants of cholesterol efflux capacity in humans. Prog Lipid Res 69: 21‑32, 2018.

15. Yao ZH, Tao Y, Sun X, Tian F, Guo S, Wang W, Tian Z, Jin H, Zhang B and Tian Y: Sonodynamic therapy‑induced foam cells apoptosis‑activates thephagocyticPPAR‑LRXR‑α ABCA1/ABC1 pathway and promotes cholesterol efflux in advanced plaque. Atherosclerosis 277: 136‑144, 2018.

16. Yang HL, Tao Y, Sun X, Tian F, Guo S, Wang W, Tian Z, Jin H, Zhang B and Tian Y: Sonodynamic therapy‑induced foam cells apoptosis‑activates thephagocyticPPAR‑LRXR‑α ABCA1/ABC1 pathway and promotes cholesterol efflux in advanced plaque. Atherosclerosis 277: 136‑144, 2018.
49. Zhang ZZ, Chen JJ, Deng WY, Yu XH and Tan WH: CTRP1 decreases ABCA1 expression and promotes lipid accumulation through the miR-424-5p/FoxO1 pathway in THP-1 macrophage-derived foam cells. Cell Biol Int, Jul 20, 2021 (Epub ahead of print). doi: https://doi.org/10.1002/cbin.11666.

50. Moradi-Chaleshtori M, Shojaei S, Mohammadi-Yeganeh S and Hashemi SM: Transfer of miRNA in tumor-derived exosomes suppresses breast tumor cell invasion and migration by inducing M1 polarization in macrophages. Life Sci 282: 119800, 2021.

51. Zhao R, Feng J and He G: miR-613 regulates cholesterol efflux by targeting LXRα and ABCA1 in PPARγ activated THP-1 macrophages. Biochem Biophys Res Commun 448: 329-334, 2014.

52. Xu Y, Lai F, Xu Y, Wu Y, Liu Q, Li N, Wei Y, Feng T, Zheng Z, Jiang W, et al: Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARγ-LXRα-ABCA1 pathway. Biochem Biophys Res Commun 414: 779-782, 2011.

53. Gu HF, Li N, Xu ZQ, Hu L, Li H, Zhang RJ, Chen RM, Zheng XL, Tang YL and Liao DF: Chronic unpredictable mild stress promotes atherosclerosis via HMGB1/TLR4-mediated downregulation of PPARγ/LXRα/ABCA1 in ApoE−/−mice. Front Physiol 10: 165, 2019.

54. Wang S, Zhang X, Liu M, Luan H, Ji Y, Guo P and Wu C: Chrysin inhibits foam cell formation through promoting cholesterol efflux from RAW264.7 macrophages. Pharm Biol 53: 1481-1487, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.